ADIA Nutrition Appoints Dawn Bell as Chief Revenue Officer to Accelerate Growth and Drive Success Across Physician Network
MWN-AI** Summary
ADIA Nutrition, Inc. (OTCQB: ADIA), a prominent player in regenerative medicine based in Winter Park, Florida, has announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) of its subsidiary, ADIA Labs, effective January 8, 2026. Bell, who brings over 15 years of experience as a sales strategist in the medical device and pharmaceutical sectors, is expected to play a pivotal role in boosting revenue for ADIA Nutrition while fostering success across its entire physician network.
In her new role, Bell will focus on driving revenue growth not just for ADIA Nutrition's lab operations but also for practitioners and clinics partnering with the company. She aims to provide comprehensive support to medical professionals, facilitating the integration of ADIA’s innovative regenerative therapies and diagnostic services into their practices, including areas such as orthopedics, pain management, and wellness. This strategy is designed to enhance revenue streams for partner clinics, improving both patient care and business profitability.
The timing of Bell's appointment aligns with ADIA Med's upcoming launch of its first Institutional Review Board (IRB)-approved clinical study targeting autism, a significant move in enhancing the company's clinical research capabilities. Larry Powalisz, CEO of ADIA Nutrition, expressed enthusiasm for Bell’s vision and experience, highlighting her potential to elevate the company's growth trajectory while empowering physician partners through training and resources.
ADIA Nutrition is experiencing strong momentum with its expanding nationwide network of clinics and ongoing initiatives to provide advanced regenerative solutions. As the company continues to innovate in healthcare, Bell's leadership is anticipated to further solidify ADIA's position in the regenerative medicine market.
For healthcare practitioners interested in collaborating with ADIA, the company encourages outreach for opportunities to license the Adia Med brand or integrate its therapies into their practices.
MWN-AI** Analysis
ADIA Nutrition, Inc. (OTCQB: ADIA) has made a significant strategic move by appointing Dawn Bell as Chief Revenue Officer, a decision poised to bolster its growth trajectory within the regenerative medicine sector. Ms. Bell’s extensive experience in medical sales positions her to spearhead critical partnerships with healthcare providers, aiming to expand revenue streams and integrate ADIA's advanced therapies into practice.
This appointment comes at an opportune moment for ADIA Nutrition, which is on the cusp of launching its first Institutional Review Board (IRB)-approved clinical study focused on autism. The dual focus on building the physician network while advancing clinical research may provide synergistic benefits—enhancing both reputation and revenue potential.
Investors should note that the company’s strategy centers on increasing the financial success of clinic partners through training and support, fundamentally creating a collaborative ecosystem. Such an approach not only strengthens the company's market presence but also encourages the scalability of its business model. By empowering physicians with robust regenerative solutions, ADIA widens its market reach and enhances patient outcomes, thus creating a compelling value proposition.
Moreover, ADIA’s ambitious expansion plans and its marketing of various stem cell and regenerative products hint at strong future revenue opportunities. The ongoing trend toward integrative and regenerative therapies could place ADIA favorably as healthcare continues to evolve.
In conclusion, ADIA Nutrition's proactive stance on leadership and innovation positions the company for potential growth. This is an excellent juncture for investors to consider entering the market, given the company's expanding clinic partnerships and promising product pipeline. As always, potential investors should conduct further due diligence and assess market conditions relative to the firm’s forward-looking strategies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Winter Park, Florida--(Newsfile Corp. - January 8, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a rapidly growing leader in regenerative medicine, today announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/279724_dawnbell.jpg
While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties.
This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.
"We are truly excited to welcome Dawn to the team," said Larry Powalisz, CEO of ADIA Nutrition. "She brings the experience and vision needed to take our growth to the next level. More than just driving revenue for ADIA, Dawn's real impact will be in making everyone successful-equipping our physician and clinic partners with the tools, training, and support to grow their practices, improve patient outcomes, and build stronger, more profitable businesses using our regenerative solutions."
ADIA Nutrition continues to gain momentum with robust revenue growth, an expanding nationwide network of clinic partnerships, strategic initiatives, and the upcoming launch of its first IRB-approved autism clinical study at Adia Med of Winter Park.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279724
FAQ**
How is Adia Nutrition Inc. ADIA contributing to the healthcare landscape in Winter Park, and what specific regenerative therapies are being integrated into local practices?
With the upcoming IRB-approved autism clinical study at Adia Med of Winter Park, what potential impacts can we expect on the local community and the broader field of regenerative medicine?
In what ways is Dawn Bell's appointment as Chief Revenue Officer expected to influence the growth trajectory of Adia Nutrition Inc. ADIA in Winter Park's healthcare sector?
Can you elaborate on the strategic partnerships that Adia Nutrition Inc. ADIA is pursuing in Winter Park, particularly in terms of enhancing patient outcomes and clinic revenue?
**MWN-AI FAQ is based on asking OpenAI questions about Adia Nutrition Inc (OTC: ADIA).
NASDAQ: ADIA
ADIA Trading
0.0% G/L:
$0.18 Last:
10,000 Volume:
$0.18 Open:
